Although some of the results of these trials are pending, the outlook for patients with prostate cancer could be improved with so many new therapies in the pipeline. Justin (JC) Liauw, PharmD, BCOP, is a clinical pharmacy specialist who works rounding with the medical team inpatient at the ...
2019. https://www.inspq.qc.ca/publications/2639. Krieger N, Williams DR, Moss NE. Measuring social class in US public health research: concepts, methodologies, and guidelines. Annu Rev Public Health. 1997;18:341–78. Article CAS PubMed Google Scholar Leech JA, Nelson WC, Burnett RT, ...
Older patients with a limited life expectancy and low-risk cancer had the lowest risk of recurrence. These patients were also found to have the highest risk of complication from PSA monitoring. Furthermore, these patients received nearly the same amount of PSA tests as younger men with...
Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119(24):5697–705. PubMed Central CAS Pub...
Clinical staging to differentiate between localized and advanced disease stage appear to be unreliable. Curative therapy can only be performed in patients ... JJ Fütterer - 《European Journal of Radiology》 被引量: 182发表: 2007年 Imaging of prostate cancer with PET/CT and radioactively labeled ...
Zhang FB, Du Y, Tian Y, Ji ZG, Yang PQ. MiR-1299 functions as a tumor suppressor to inhibit the proliferation and metastasis of prostate cancer by targeting NEK2. Eur Rev Med Pharmacol Sci. 2019;23(2):530–538. doi:10.26355/eurrev_201901_16865 36. Zhang X, Zhou J, Xue D, Li ...
Indication for PVP procedure was same with indication to TUR-P or suprapubic prostatectomy, it means Q max. less than 15ml/sec, PQ study prooved subvesical obstruction or complicated BPH. Average patientes age was 67.9 years (48- 85 years). Prostate volume range from 35 grams to 110 grams...
f Western blot of LNAI cells, mock-treated or treated with either 50 µM H2O2 or 250 µM paraquat (PQ) for 24 h. Approximately 20 µg total protein was immunoblotted and probed with the indicated antibodies. g Western blot from total LNAI protein lysates (15 µg) ...
Median radiographic progression-free survival was 24.8 months for olaparib plus abiraterone, compared to 16.6 months in the abiraterone arm.
The study, presented by scientists from the Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group on June 1, 2014, at the annual meeting of the American Society of Clinical Oncology, enrolled 790 men newly diagnosed with metastatic disease and randomized the p...